Health Canada approves first targeted biological therapy to show survival benefit in

[News]

Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.

More... (http://www.news-medical.net/news/20100809/Health-Canada-approves-first-targeted-biological-therapy-to-show-survival-benefit-in-stomach-cancer.aspx)